Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03712371 · ClinicalTrials.gov registry record · Phase 1
Study of Chitosan for Pharmacologic Manipulation of AGE Levels in Prostate Cancer Patients
A Phase 1 study, sponsored by Medical University of South Carolina.
- Terminated
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT03712371 is a Phase 1 study that was terminated before completion, run by Medical University of South Carolina. The registered enrollment target is 12 participants.
The verdict
NCT03712371, a Phase 1 study, was terminated before completion, sponsored by Medical University of South Carolina.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This study will examine the utility of chitosan for reduction of blood or tissue levels of AGEs in patients with prostate cancer who are clinically stable on androgen-deprivation therapy.
Interventions
- DRUG Chitosan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2019-01-16 |
| Est. Completion | 2021-09-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03712371
The ClinicalTrials.gov registry entry for NCT03712371 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical University of South Carolina, which has 755 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Chitosan is the first listed.
NCT03712371 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03712371 about?
NCT03712371 is a clinical study titled "Study of Chitosan for Pharmacologic Manipulation of AGE Levels in Prostate Cancer Patients". This study will examine the utility of chitosan for reduction of blood or tissue levels of AGEs in patients with prostate cancer who are clinically stable on androgen-deprivation therapy.
What is the current status of trial NCT03712371?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2019-01-16. Estimated completion is 2021-09-07.
What interventions are being tested in trial NCT03712371?
The interventions under investigation include: Chitosan (DRUG).
Who is sponsoring clinical trial NCT03712371?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.